CA3142642A1 - Method for treating cancer patients using c-met inhibitor - Google Patents
Method for treating cancer patients using c-met inhibitor Download PDFInfo
- Publication number
- CA3142642A1 CA3142642A1 CA3142642A CA3142642A CA3142642A1 CA 3142642 A1 CA3142642 A1 CA 3142642A1 CA 3142642 A CA3142642 A CA 3142642A CA 3142642 A CA3142642 A CA 3142642A CA 3142642 A1 CA3142642 A1 CA 3142642A1
- Authority
- CA
- Canada
- Prior art keywords
- met
- cancer
- gene
- inhibitor
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019090294 | 2019-06-06 | ||
| CNPCT/CN2019/090294 | 2019-06-06 | ||
| CN2019092706 | 2019-06-25 | ||
| CNPCT/CN2019/092706 | 2019-06-25 | ||
| CN2019109906 | 2019-10-08 | ||
| CNPCT/CN2019/109906 | 2019-10-08 | ||
| PCT/CN2020/094824 WO2020244654A1 (en) | 2019-06-06 | 2020-06-08 | Method for treating cancer patients using c-met inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3142642A1 true CA3142642A1 (en) | 2020-12-10 |
Family
ID=73653139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3142642A Pending CA3142642A1 (en) | 2019-06-06 | 2020-06-08 | Method for treating cancer patients using c-met inhibitor |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220252603A1 (https=) |
| EP (1) | EP3980783A4 (https=) |
| JP (1) | JP2022535880A (https=) |
| CN (1) | CN114599978A (https=) |
| CA (1) | CA3142642A1 (https=) |
| WO (1) | WO2020244654A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112592976B (zh) * | 2020-12-30 | 2021-09-21 | 深圳市海普洛斯生物科技有限公司 | 一种检测met基因扩增的方法及装置 |
| MX2023012434A (es) * | 2021-04-21 | 2024-02-08 | Apollomics Inc | Diagnostico y tratamiento de cancer usando inhibidor de c-met. |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008113013A2 (en) * | 2007-03-15 | 2008-09-18 | University Of Chicago | C-met mutations and uses thereof |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| KR20130103734A (ko) * | 2010-08-31 | 2013-09-24 | 제넨테크, 인크. | 바이오마커 및 치료 방법 |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| CN106008339B (zh) * | 2016-06-08 | 2018-09-07 | 上海准视生物科技有限公司 | 一种放射性c-met靶向亲和小分子化合物及其应用 |
-
2020
- 2020-06-08 EP EP20818373.1A patent/EP3980783A4/en not_active Withdrawn
- 2020-06-08 JP JP2021572340A patent/JP2022535880A/ja active Pending
- 2020-06-08 WO PCT/CN2020/094824 patent/WO2020244654A1/en not_active Ceased
- 2020-06-08 CA CA3142642A patent/CA3142642A1/en active Pending
- 2020-06-08 US US17/616,203 patent/US20220252603A1/en not_active Abandoned
- 2020-06-08 CN CN202080055590.1A patent/CN114599978A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020244654A1 (en) | 2020-12-10 |
| EP3980783A4 (en) | 2023-09-13 |
| EP3980783A1 (en) | 2022-04-13 |
| CN114599978A (zh) | 2022-06-07 |
| US20220252603A1 (en) | 2022-08-11 |
| JP2022535880A (ja) | 2022-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3142642A1 (en) | Method for treating cancer patients using c-met inhibitor | |
| US20240218453A1 (en) | Diagnostic and treatment of cancer using c-met inhibitor | |
| Dhakras et al. | Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma | |
| EP1597558A2 (en) | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators | |
| US20160002741A1 (en) | Method for predicting sensitivity to egfr inhibitor | |
| JP6214690B2 (ja) | 胃癌患者に対するテガフール・ギメラシル・オテラシルカリウム配合剤及びｅｇｆｒ阻害剤からなる化学療法の選択方法 | |
| JP2008533991A (ja) | 肺癌におけるｃ−ｍｅｔ突然変異 | |
| JP2019176858A (ja) | 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物 | |
| JP2015096049A (ja) | Ｖｅｇｆ阻害剤長期奏功性予測方法 | |
| WO2021104442A1 (en) | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway | |
| JP2005333987A (ja) | 悪性血液疾患の予後 | |
| US20220145403A1 (en) | Method of classifying a sample based on determination of fgfr | |
| US20110206691A1 (en) | Methods and Compositions for Treating Neuroblastoma | |
| AU2020311564B2 (en) | Determining individual HLA patterns, use as prognosticators, target genes and therapeutic agents | |
| JP2022517563A (ja) | タンパク質キナーゼバイオマーカーと組み合わせた、多標的キナーゼ阻害剤を使用したがんの処置 | |
| JP2025541293A (ja) | Ｃ－ｍｅｔ阻害剤を用いた、ｅｇｆｒ ｔｋｉに耐性があるがんの治療 | |
| HK40130056A (zh) | 使用c-met抑制剂治疗对egfr tki具有耐药性的癌症 | |
| US20240247065A1 (en) | Methods of treatment of cancer patients having altered setd2 biomarker with a pd-1 antagonist | |
| WO2010124215A1 (en) | Gene expression levels of egfr, vegfr2, and ercc1 associated with clinical outcomes of chemotherapy | |
| CA2724346A1 (en) | Ercc-1 expression predicts chemotherapy outcome | |
| EP3282019A1 (en) | Genotyping and treatment of cancer, in particular chronic lymphocytic leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240604 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250403 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250805 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251124 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260126 |